BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hasselbalch HC, Skov V, Kjær L, Ellervik C, Poulsen A, Poulsen TD, Nielsen CH. COVID-19 as a mediator of interferon deficiency and hyperinflammation: Rationale for the use of JAK1/2 inhibitors in combination with interferon. Cytokine Growth Factor Rev 2021;60:28-45. [PMID: 33992887 DOI: 10.1016/j.cytogfr.2021.03.006] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 6.5] [Reference Citation Analysis]
Number Citing Articles
1 Chen PK, Yeo KJ, Chang SH, Liao TL, Chou CH, Lan JL, Chang CK, Chen DY. The detectable anti-interferon-γ autoantibodies in COVID-19 patients may be associated with disease severity. Virol J 2023;20:33. [PMID: 36810114 DOI: 10.1186/s12985-023-01989-1] [Reference Citation Analysis]
2 Jiang Y, Rubin L, Zhou Z, Zhang H, Su Q, Hou ST, Lazarovici P, Zheng W. Pharmacological therapies and drug development targeting SARS-CoV-2 infection. Cytokine Growth Factor Rev 2022;68:13-24. [PMID: 36266222 DOI: 10.1016/j.cytogfr.2022.10.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Hasselbalch H, Skov V, Kjær L, Larsen MK, Knudsen TA, Lucijanić M, Kusec R. Recombinant Interferon-β in the Treatment of Polycythemia Vera and Related Neoplasms: Rationales and Perspectives. Cancers (Basel) 2022;14. [PMID: 36428587 DOI: 10.3390/cancers14225495] [Reference Citation Analysis]
4 Burgos-salcedo J. Immune network operations in COVID-19. Explor Immunol 2022. [DOI: 10.37349/ei.2022.00068] [Reference Citation Analysis]
5 Jiménez D, Torres Arias M. Immunouniverse of SARS-CoV-2. Immunol Med 2022;:1-39. [PMID: 35502127 DOI: 10.1080/25785826.2022.2066251] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Jessen WJ, Gaisenband SD, Quintanilla M, Lula S, Mcleroth P, Sullivan A, Letovsky S. Modeling COVID-19 disease biology to identify drug treatment candidates.. [DOI: 10.1101/2022.04.18.488660] [Reference Citation Analysis]
7 Worku DA. SARS-CoV-2 Associated Immune Dysregulation and COVID-Associated Pulmonary Aspergilliosis (CAPA): A Cautionary Tale. Int J Mol Sci 2022;23:3228. [PMID: 35328649 DOI: 10.3390/ijms23063228] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Bhargavi S, Madhan Shankar SR, Jemmy CH. In silico and in vitro studies on inhibitors for SARS-CoV-2 non-structural proteins with dual herbal combination of Withania somnifera with five rasayana herbs. Journal of Biomolecular Structure and Dynamics. [DOI: 10.1080/07391102.2022.2046642] [Reference Citation Analysis]
9 Chen C, Lin S, Shen C, Hsieh K, Cheng C. Biomarkers during COVID-19: Mechanisms of Change and Implications for Patient Outcomes. Diagnostics 2022;12:509. [DOI: 10.3390/diagnostics12020509] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
10 Lu LY, Feng PH, Yu MS, Chen MC, Lin AJ, Chen JL, Yu LH. Current utilization of interferon alpha for the treatment of coronavirus disease 2019: A comprehensive review. Cytokine Growth Factor Rev 2022;63:34-43. [PMID: 35115233 DOI: 10.1016/j.cytogfr.2022.01.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
11 Ben Moftah M, Eswayah A. Repurposing of Hydroxyurea Against COVID-19: A Promising Immunomodulatory Role. Assay Drug Dev Technol 2022;20:55-62. [PMID: 34990284 DOI: 10.1089/adt.2021.090] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Zhuang X, Tsukuda S, Wrensch F, Wing PAC, Schilling M, Harris JM, Borrmann H, Morgan SB, Cane JL, Mailly L, Thakur N, Conceicao C, Sanghani H, Heydmann L, Bach C, Ashton A, Walsh S, Tan TK, Schimanski L, Huang KA, Schuster C, Watashi K, Hinks TSC, Jagannath A, Vausdevan SR, Bailey D, Baumert TF, McKeating JA. The circadian clock component BMAL1 regulates SARS-CoV-2 entry and replication in lung epithelial cells. iScience 2021;24:103144. [PMID: 34545347 DOI: 10.1016/j.isci.2021.103144] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 13.0] [Reference Citation Analysis]
13 Palandri F, Breccia M, De Stefano V, Passamonti F. Philadelphia-Negative Chronic Myeloproliferative Neoplasms during the COVID-19 Pandemic: Challenges and Future Scenarios. Cancers (Basel) 2021;13:4750. [PMID: 34638236 DOI: 10.3390/cancers13194750] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
14 Hossain MJ, Jannat T, Brishty SR, Roy U, Mitra S, Rafi MO, Islam MR, Nesa ML, Islam MA, Emran TB. Clinical Efficacy and Safety of Antiviral Drugs in the Extended Use against COVID-19: What We Know So Far. Biologics 2021;1:252-84. [DOI: 10.3390/biologics1020016] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]